Episode 062: “Paging Heme/Onc: Updates from ASCO 2023” - Management of NSCLC and KEYNOTE 671

Episode 062: “Paging Heme/Onc: Updates from ASCO 2023” - Management of NSCLC and KEYNOTE 671

This week’s episode is part 4 of 5 of a joint mini-series with our friends Two Onc Docs. In today’s episode, we will be recapping the current treatment of resectable NSCLC and discussing KEYNOTE 671, which was presented at ASCO 2023, looking at neoadjuvant chemo+immunotherapy followed by adjuvant immunotherapy. We also discuss the use of the “interaction test,” “multiplicity,” and it’s important role in understanding subgroup analyses.